title: Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer.
abstract: The recent manuscript in New England Journal of Medicine by Antonarakis et al. [1] has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 (AR-V7), in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (mCRPC) patients receiving enzalutamide or abiraterone. The findings were striking, none of the 18 patients with detectable AR-V7 in CTCs had prostate-specific antigen (PSA) responses. Further, the median time to PSA progression after enzalutamide or abiraterone treatment was only 1.3-1.4 months in AR-V7-positive patients as compared to 5.3-6.1 months in AR-V7 negative patients. AR-V7 in CTCs was also associated with shorter survival.
authors.affiliation: Department of Medicine and Urology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA, .
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
authors.affiliation: Department of Structural and Cellular Biology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA; National Engineering Laboratory for AIDS Vaccine, College of Life Sciences, Jilin University, Changchun, Jilin, China, .
authors.forename: Yan
authors.initials: Y
authors.lastname: Dong
mesh_terms: D000737:Androstenols / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D008297:Male; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives*; D011471:Prostatic Neoplasms / Q000235:genetics*; D012334:RNA, Neoplasm / Q000032:analysis*; D011944:Receptors, Androgen / Q000235:genetics*
chemical_list: D000737:Androstenols; D012334:RNA, Neoplasm; D011944:Receptors, Androgen; D010669:Phenylthiohydantoin